Hi Zior
In fact I have - but I'm kinda busy today. Will try and get back to this.
The very short answer is that the gene editing process used by Precision - and now by IMU - is specifically aimed at deleting the components which cause graft vs host rejection issues. It seems to be highly successful.
The clever part is the work Precision Biosciences did to identify exactly what gene edits are required to avoid G vs H problems - and then achieve that with their own ARCUS genome editing tech. Precision claims that their ARCUS tech is significantly better than CRISPR - the tech everyone hears about when gene editing gets a mention in the media.
I will try and find the reference I used when I was reading up on this. Maybe tomorrow.
Cheers
Dave
Hi ZiorIn fact I have - but I'm kinda busy today. Will try and...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
-0.001(1.30%) |
Mkt cap ! $556.3M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.5¢ | $2.780M | 36.36M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 108996 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 254900 | 3 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
-0.001 ( 1.17 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.5¢ | 17617693 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| IMU (ASX) Chart |